Demographic and Clinical Factors Among SLE Patients (n=70)
| Enrolled in the study(n=30) | Refused (n=15) | Clinical Trial Participants(n=25) | p-value | |
|---|---|---|---|---|
| Demographics | ||||
| Age (mean ± SD) | 41.87 ± 13.14 | 38.87 ± 13.85 | 37.84 ± 12.46 | 0.502 |
| Female (n,%) | 29, 97% | 12, 80% | 23, 92% | 0.174 |
| Black (n,%) | 12, 40% | 4, 15% | 5, 20% | 0.305 |
| Ethnic Hispanic (n,%) | 14, 57% | 5, 33% | 7, 28% | 0.078 |
| Income, $ (mean ± SD) | 55711 ± 22853 | 56037 ± 28671 | 77378 ± 42968 | 0.035 |
| Years Since SLE Diagnosis (mean ± SD) | 10.04 ±10.71 | 8.60 ± 6.52 | 12.04 ± 7.48 | 0.243 |
| SLE Organ Involvement | ||||
| Arthritis (n,%) | 25, 83% | 10, 67% | 24, 96% | 0.047 |
| Mucocutaneous (n,%) | 22, 73% | 11, 73% | 22, 88% | 0.369 |
| Lupus Nephritis (n,%) | 5, 17% | 4, 27% | 5, 20% | 0.741 |
| Medication | ||||
| Hydroxychloroquine (n,%) | 25, 83% | 14, 93% | 24, 96% | 0.272 |
| Corticosteroid (n,%) | 5, 17% | 1, 7% | 14, 56% | 0.001 |
| MMF, MPA, AZA (n,%) | 13, 43% | 7, 47% | 5, 20% | 0.124 |
| Fibromyalgia (n,%) | 4, 13% | 0, 0% | 0, 0% | 0.059 |
| Admissions in the Past Year (mean ± SD) | 1.63 ± 1.52 | 1.13 ± 1.30 | 0.52 ± 0.96 | 0.009 |
| Office Visits in the Past Year (mean ± SD) | 3.13 ± 2.21 | 3.20 ± 2.27 | 4.76 ± 3.35 | 0.063 |